期刊文献+

PH-350免疫吸附技术联合免疫抑制剂治疗狼疮性肾炎临床疗效观察 被引量:6

Clinical efficacy of immunoadsorption combined with immune inhibitors in the treatment of lupus nephritis
下载PDF
导出
摘要 目的探讨苯丙氨酸(PH-350)免疫吸附治疗狼疮性肾炎(LN)的效果及临床应用价值。方法收集狼疮性肾炎患者106例,随机分为治疗组(51例)和对照组(55例),治疗组运用PH-350免疫吸附配合激素和免疫抑制剂治疗,对照组予激素和免疫抑制剂治疗。比较两组患者治疗前后SLEDAI评分及24h尿蛋白定量、抗双链DNA抗体(ds-DNA)定量、抗核小体抗体(NUCL)定量、免疫球蛋白、补体C3、C4、血沉(ESR)、C反应蛋白(CRP)、血红蛋白(Hb)、电解质、肾功能、肝功能等指标并行统计学分析。结果接受免疫吸附治疗后(2周、4周、12周、24周)的患者,其血沉、CRP、免疫球蛋白、抗ds-DNA抗体定量、NUCL定量、SLEDAI评分与对照组患者比较明显下降,差异均具有统计学意义(P<0.05);4周时Hb上升(P<0.05);12周时24h尿蛋白明显下降(P<0.05),其他各项生化指标无明显改变,无肝肾功能损害(P>0.05),临床症状更快缓解(P<0.05);24周复发率较低(P<0.05)。结论免疫吸附治疗狼疮性肾炎起效更迅速、疗效较显著,且安全无明显副反应,复发率低。 Objective To explore the efficacy and clinical application of phenylalanine immunosorbent assay(PH-350) in the treatment of lupus nephritis(LN).Methods One hundred and six patients with LN were randomly divided into the study group(n=51) and the control group(n=55).The treatment group was treated by PH-350 immunosorbent combined with hormone and immune inhibitors.The control group was treated by hormone and immune inhibitors.Indexes were compared between the two groups before and after treatment,including SLEDAI score,24-hour urine protein,anti-dsDNA antibodies,anti-nucleosome antibodies(AnuA),immunoglobulin,complement C3,C4,erythrocyte sedimentation rate(ESR),C-reactive protein(CRP),hemoglobin(Hb),electrolytes,kidney function,liver function.Results After treatment(2 weeks,4 weeks,12 weeks,24 weeks),the ESR,CRP,immunoglobulin,quantification of anti-dsDNA antibodies,quantification of NUCL,SLEDAI score were declined significantly in the study group,compared with the control group(P0.05).The levels of Hb increased in the fourth week,and the levels of 24-hour urine protein were significantly decreased in the 12th week(P0.05),with no significant change in liver and kidney function and other biochemical indexes(P0.05).The clinical symptoms showed faster alleviation(P 0.05),and the recurrence rate was lower in the 24th week(P0.05).Conclusion The immunoadsorption treatment is quite effective and safe for treating lupus nephritis,without obvious side effects,and the recurrence rate is low.
出处 《海南医学》 CAS 2013年第6期790-792,共3页 Hainan Medical Journal
基金 国家"十一.五"科技项目(编号:2008BAI59B02) 深圳医学重点学科建设支助项目(编号:2005C10)
关键词 狼疮性肾炎 苯丙氨酸 免疫吸附治疗 临床疗效 Lupus nephritis Phenylalanine Immunoadsorption Clinical efficacy
  • 相关文献

参考文献10

  • 1陆再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2008:775.
  • 2Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDA I: a disease activity index for lupus patients [J]. Arthritis Rheum, 1992, 35: 630-640.
  • 3Moks T, Abrahms6n L, Nilsson B, et al. Staphylococcal protein A consists of five IgG-binding domains [J]. Eur J Biochem, 1986, 156 (3): 637-643.
  • 4陶静,谢红浪,季大玺.葡萄球菌蛋白A免疫吸附的临床应用[J].肾脏病与透析肾移植杂志,2006,15(3):273-277. 被引量:15
  • 5季大玺,龚德华,任冰,徐斌,刘芸,张一丹,谢红浪,陶静,胡伟新,刘志红,黎磊石.免疫吸附的临床应用及疗效[J].肾脏病与透析肾移植杂志,2004,13(5):408-413. 被引量:44
  • 6赵淑珍,刘光珍,王世荣,李德谦.DNA免疫吸附治疗狼疮性肾炎的临床观察[J].中国血液净化,2009,8(10):541-544. 被引量:16
  • 7谭国据,谭全达,刘绛.免疫吸附治疗狼疮性肾炎30例的疗效观察[J].中国实用医药,2011,6(16):81-82. 被引量:5
  • 8Suzuki K. The role of immunoadsorption using dextran sulfate cellulose columns in the treatment of systemic lupus erythematosus [J]. Ther Apher, 2000, 4(3): 239-243.
  • 9Stummvoll GH, AfingerM, Smolen JS, et al. IgG imrnunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study [J]. Arm Rheum Dis, 2005, 64(7): 1015-1021.
  • 10梅洁卉,胡伟新,季大玺,等.免疫吸附治疗ANCA相关血管炎的初步察[J].肾脏病与透析肾移植杂志,2006,15(3):203-209.

二级参考文献41

  • 1季大玺,龚德华,任冰,徐斌,刘芸,张一丹,谢红浪,陶静,胡伟新,刘志红,黎磊石.免疫吸附的临床应用及疗效[J].肾脏病与透析肾移植杂志,2004,13(5):408-413. 被引量:44
  • 2占锦峰,刘志红,李世军,王庆文,陈惠萍,曾彩虹,龚德华,季大玺,黎磊石.免疫吸附治疗脂蛋白肾病的疗效观察[J].肾脏病与透析肾移植杂志,2006,15(3):203-209. 被引量:22
  • 3陈灏珠主编.实用内科学.第10版[M].北京:人民卫生出版社,1998:2076-2077.
  • 4Wada Y, Ito S, Ueno M, et al. Renal outcome and predictors of clinical renal involvement in patients with silent lupus nephritis [J].Nephron Clin Pract, 2004,98:c105-111.
  • 5Madaio MP. The role of autoantibodies in the pathogenesis of lupus nephritis [J] . Semin Nephrol, 1999,19:48-56.
  • 6Bansal VK, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials[J].Am J Kidney Dis, 1997,29: 193-199.
  • 7Boumpas DT, Austin HA 3rd, Vaughan EM, et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy [J].Ann Intern Med, 1993,119:366-369.
  • 8Petri M. Cyclophosphamide: new approaches for systemic lupus erythematosus [J].Lupus, 004,13:366-371.
  • 9Sprenger KBG, Huber K, KratzW, et al. Nomograms for the p rediction of patient's p lasma volume in plasma exchange therapy fromheight, weight, and hematocrit. J Clin Apheresis, 1987, 3: 185-190.
  • 10Bombardier C, Gladman DD, UrowitzMB, et al. Derivation of theSLEDA I : a disease activity index for lupus patients. Arthritis- Rheum, 1992, 35:630-640.

共引文献2857

同被引文献47

  • 1Hu WX, Liu ZZ, Chen HP, et al. Clinical characteristics and prognosis of diffuse proliferative lupus nephritis with thrombot- ic microangiopathy[ J]. Lupus,2010,19(14):1 591 -1 598.
  • 2Hochberg MC. Updating the American College of Rheuma- tology revised criteria for the classification of systemic lupus erythematosus [ J ]. Arthritis Rheum, 1997,40 (9) : 1 725.
  • 3Bonmbardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE [ J ]. Arthritis Rheum, 1992,35 (6) :630 - 640.
  • 4Miyagawa H,Yam ai M,Sakagu chi D, et al. Association of polymorph- isms in complement component C3 gen e with susceptibility lupuserythem- atosus erythematous [J ].Rheumatology,2008,47(2) : 158-164.
  • 5Peng Y,Laouar Y,Li M O, et 81. TGF-beta regulates in vivo expansion of Foxp3-expressing CD4 + CD25 + regulatory T cells responsible for prote- ction against diabetes[J]. Proc Nad Acad Sci U S A,2004,101(13):4572-4577.
  • 6Malm sten M , Schmidtchen A. Antimicrobial C3a-Biology, Biophysics, and Evolution[M].New York:Sp ringer New York, 2007.
  • 7Yah J,Vetvicka V,Xia Y,et al.Critical role of Kupffer cell CR3(CDllb CD18)In the clearance of IgM-opsonized erythrocytes or soluble beta- glucan[J].Immunopharmacology, 2000,46( 1 ) : 39-54.
  • 8Thiel S,Vorup Jensen T,Stover C M,et al. A second sefine protease associated with mannan binding lectin that activates complement [J]. Nature, 1997,386(6624):506-510.
  • 9Toubi E,Kessel A,Shoenfeld Y.High-dose intravenous immunoglo- bulins:anoption in the treatment of systemic lupuserythematosus[J].Hum Immunol, 2005,66( 4 ) : 395- 402.
  • 10Orbaeh H,Tishler M,Shoenfeld Y.Intravenous immunoglobulin and the kidney-a two -edged sword [J].Semin Arthritis Rheum, 2004,34 (3) : 593 - 601.

引证文献6

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部